Johnson & Johnson Stock-Based Compensation 2010-2025 | JNJ

Johnson & Johnson annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
  • Johnson & Johnson stock-based compensation for the quarter ending June 30, 2025 was $288M, a 4.64% decline year-over-year.
  • Johnson & Johnson stock-based compensation for the twelve months ending June 30, 2025 was $3.045B, a 2.9% decline year-over-year.
  • Johnson & Johnson annual stock-based compensation for 2024 was $1.176B, a 1.2% increase from 2023.
  • Johnson & Johnson annual stock-based compensation for 2023 was $1.162B, a 2.11% increase from 2022.
  • Johnson & Johnson annual stock-based compensation for 2022 was $1.138B, a 0.26% increase from 2021.
Johnson & Johnson Annual Stock-Based Compensation
(Millions of US $)
2024 $1,176
2023 $1,162
2022 $1,138
2021 $1,135
2020 $1,005
2019 $977
2018 $978
2017 $962
2016 $878
2015 $874
2014 $792
2013 $728
2012 $662
2011 $621
2010 $614
2009 $628
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $404.052B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $735.860B 56.43
AbbVie (ABBV) United States $330.512B 18.22
Novo Nordisk (NVO) Denmark $298.173B 19.76
Roche Holding AG (RHHBY) Switzerland $256.584B 0.00
Novartis AG (NVS) Switzerland $246.794B 13.37
Merck (MRK) United States $204.925B 10.48
Pfizer (PFE) United States $142.930B 7.83
Sanofi (SNY) France $119.558B 11.77
Bayer (BAYRY) Germany $32.027B 6.52
Innoviva (INVA) United States $1.210B 12.68